Loading clinical trials...

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies | Clinical Trials | Clareo Health

RECRUITING

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology

NCT04470947•Medical University of Vienna

View on ClinicalTrials.gov

Summary

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies.
•duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment.
•best response to previous treatment has to be available.
•The patient is able to give written informed consent and wishes to undergo further therapy
•further therapy is medically feasible
•tumor cell-containing samples can be obtained

Exclusion Criteria

•current participation in another experimental clinical trial
•performance status does not allow participation (ECOG ˃ 1)
•pregnancy, tested at screening
•patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma.
•other malignoma, diagnosed \<1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)

Locations (1)

Medical University of Vienna

Vienna, Austria

Key Dates

Start Date

June 10, 2020

Primary Completion Date

March 31, 2026

Completion Date

March 31, 2026

Last Updated

March 22, 2024

Enrollment

150

ESTIMATED participants

Conditions

Advanced LymphomaRefractory LymphomaRefractory LeukemiaRefractory Acute Myeloid LeukemiaRefractory T-Cell Lymphoma

Interventions

Next generation functional drug screening

DIAGNOSTIC_TEST

Comprehensive genomic profiling

DIAGNOSTIC_TEST

Contacts

Philipp B. Staber, MD, PhD

CONTACT

+43 140400 philipp.staber@meduniwien.ac.at

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT04870944

Diffuse Midline Glioma, H3 K27-AlteredMetastatic Malignant Neoplasm in the Central Nervous System+8 more

View study

RECRUITINGPHASE1/PHASE2

Avo In R/R And Previously Untreated MCL

NCT04855695

Mantle Cell LymphomaRefractory Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 22, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

Inclusion Criteria

Exclusion Criteria

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Avo In R/R And Previously Untreated MCL

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)